

m, n, p and q are independently selected from 1 or 2;

R⁶ and R⁷ are independently selected from H or alkyl;

R⁸ is H, alkyl, haloalkyl or cycloalkyl;

R⁹ is H, alkyl, halogen, haloalkyl and alkoxy;

5 R¹⁰ is H or alkyl;

R¹¹, R¹² and R¹³ are independently selected from H, alkyl, alkoxy, cycloalkyl, cycloalkoxy, halogen, haloalkyl, and cyano;

or pharmaceutically acceptable salts.

10 In another aspect, there is provided a compound as defined herein for use as therapeutically active substance.

In another aspect, there is provided a pharmaceutical composition comprising a compound as defined herein and a therapeutically inert carrier.

15 In another aspect, there is provided a compound as defined herein for the treatment or prophylaxis of renal conditions, liver conditions, inflammatory conditions, conditions of the nervous system, fibrotic diseases and acute and chronic organ transplant rejection.

In another aspect, there is provided the use of a compound as defined herein for the preparation of a medicament for the treatment or prophylaxis of renal conditions, liver conditions, inflammatory conditions, conditions of the nervous system, fibrotic diseases and acute and chronic organ transplant rejection.

((3aR,8aS)-6-(2-cyclopropyl-6-((tetrahydro-2H-pyran-4-yl)methoxy)isonicotinoyl)octahydropyrrolo[3,4-d]azepin-2(1H)-yl)(3-hydroxy-4,5-dihydroisoxazolo[5,4-c]pyridin-6(7H)-yl)methanone;

and pharmaceutically acceptable salts thereof.

20. A compound according to any one of claims 1 to 19, selected from

5-((3aS,6aS)-5-(5-cyclopropyl-6-(tetrahydro-2H-pyran-4-yloxy)nicotinoyl)octahydropyrrolo[3,4-c]pyrrole-2-carbonyl)pyridine-2-sulfonamide;

((3aS,6aS)-5-(1H-benzo[d][1,2,3]triazole-5-carbonyl)hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)(2-cyclopropyl-6-((tetrahydro-2H-pyran-4-yl)methoxy)pyridin-4-yl)methanone;

((3aS,6aS)-5-(5-cyclopropyl-6-(tetrahydro-2H-pyran-4-yloxy)nicotinoyl)hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)((R)-4,5,6,7-tetrahydro-1H-benzo[d][1,2,3]triazol-5-yl)methanone;

and pharmaceutically acceptable salts thereof.

21. A compound according to any one of claims 1 to 20 for use as therapeutically active substance.
22. A pharmaceutical composition comprising a compound according to any one of claims 1 to 20 and a therapeutically inert carrier.

23. A compound according to any one of claims 1 to 20 for the treatment or prophylaxis of renal conditions, liver conditions, inflammatory conditions, conditions of the nervous system, fibrotic diseases and acute and chronic organ transplant rejection.
24. The use of a compound according to any one of claims 1 to 20 for the preparation of a medicament for the treatment or prophylaxis of renal conditions, liver conditions, inflammatory conditions, conditions of the nervous system, fibrotic diseases and acute and chronic organ transplant rejection.